Consistently, the administration of recombinant soluble ACE2 effectively blocked the interaction between spike (S) protein and ACE2, highlighting its therapeutic potential for both SARS and COVID-19 [26]. The gene discussed is ACE2; the disease is severe acute respiratory syndrome.